FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated Non-Small Cell Lung Cancer

On June 23, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.

For more information, read the FDA announcement and visit the Daiichi Sankyo website.

Posted on 6/25/2025